MRNA Stock Overview
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Moderna, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$7,300.00 |
52 Week High | US$7,400.00 |
52 Week Low | US$7,050.00 |
Beta | 1.56 |
1 Month Change | n/a |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 79.69% |
Recent News & Updates
Recent updates
Shareholder Returns
MRNA | AR Biotechs | AR Market | |
---|---|---|---|
7D | 79.7% | 0% | 0% |
1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how MRNA performed against the AR Biotechs industry.
Return vs Market: Insufficient data to determine how MRNA performed against the AR Market.
Price Volatility
MRNA volatility | |
---|---|
MRNA Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 0% |
Market Average Movement | 0% |
10% most volatile stocks in AR Market | 0% |
10% least volatile stocks in AR Market | 0% |
Stable Share Price: MRNA's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine MRNA's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2010 | 5,600 | Stephane Bancel | www.modernatx.com |
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics.
Moderna, Inc. Fundamentals Summary
MRNA fundamental statistics | |
---|---|
Market cap | AR$39.75t |
Earnings (TTM) | -AR$5.28t |
Revenue (TTM) | AR$4.56t |
9.3x
P/S Ratio-8.1x
P/E RatioIs MRNA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MRNA income statement (TTM) | |
---|---|
Revenue | US$5.15b |
Cost of Revenue | US$8.77b |
Gross Profit | -US$3.62b |
Other Expenses | US$2.35b |
Earnings | -US$5.97b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -15.57 |
Gross Margin | -70.27% |
Net Profit Margin | -115.82% |
Debt/Equity Ratio | 0% |
How did MRNA perform over the long term?
See historical performance and comparison